Reply to: Burosumab for Tumor-Induced Osteomalacia: not Enough of a Good Thing
J Bone Miner Res
.
2021 Dec;36(12):2455-2456.
doi: 10.1002/jbmr.4317.
Epub 2021 May 24.
Authors
Suzanne M Jan de Beur
1
,
Paul D Miller
2
,
Thomas J Weber
3
,
Munro Peacock
4
,
Karl Insogna
5
,
Rajiv Kumar
6
,
Frank Rauch
7
,
Diana Luca
8
,
Tricia Cimms
8
,
Mary Scott Roberts
8
,
Javier San Martin
8
,
Thomas O Carpenter
5
Affiliations
1
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
2
Colorado Center for Bone Research, Lakewood, CO, USA.
3
Duke University, Durham, NC, USA.
4
Indiana University School of Medicine, Indianapolis, IN, USA.
5
Yale University School of Medicine, New Haven, CT, USA.
6
Mayo Clinic College of Medicine, Rochester, MN, USA.
7
McGill University, Montreal, Canada.
8
Ultragenyx Pharmaceutical Inc., Novato, CA, USA.
PMID:
34030212
PMCID:
PMC9290665
DOI:
10.1002/jbmr.4317
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Humans
Osteomalacia* / drug therapy
Paraneoplastic Syndromes*
Substances
Antibodies, Monoclonal, Humanized
burosumab
Supplementary concepts
Oncogenic osteomalacia